http://orcid.org/0000-0001-5882-5388
References
- Shack L, Bryant H, Lockwood G, et al. Conditional relative survival: a different perspective to measuring cancer outcomes. Cancer Epidemiol. 2013;37:446–448.
- Ellison LF, Bryant H, Lockwood G, et al. Conditional survival analyses across cancer sites. Health Rep. 2011;22:21–25.
- Janssen-Heijnen ML, Gondos A, Bray F, et al. Clinical relevance of conditional survival of cancer patients in Europe: age-specific analyses of 13 cancers. J Clin Oncol. 2010;28:2520–2528.
- Boggs DR, Sofferman SA, Wintrobe MM, et al. Factors influencing the duration of survival of patients with chronic lymphocytic leukemia. Am J Med. 1966;40:243–254.
- Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–234.
- Rai KR, Wasil T, Iqbal U, et al. Clinical staging and prognostic markers in chronic lymphocytic leukemia. Hematol Oncol Clin N Am. 2004;18:795–805.
- Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90:446–460.
- Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. JCO. 2015;33:2516–2522.
- Maurer MJ, Bachy E, Ghesquieres H, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91:1096–1101.
- Tam CS, O'Brien S, Plunkett W, et al. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 2014;124:3059–3064.
- Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV-3–IV-18.
- Human Mortality Database. University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany); 2016. Available from: www.mortality.org
- U.S. Census Bureau. Population Estimates and Projection, Annual Estimates of the Resident Population by Single Year of Age and Sex for the United States. Washington (DC) various years.
- National Center for Health Statistics. Vital statistics of the United States, Volume II: mortality, Part A. Washington (DC): Government Printing Office; various years.
- Chen-Hardee S, Chrischilles EA, Voelker MD, et al. Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin’s lymphoma (United States). Cancer Causes Control. 2006;17:647–654.
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
- Klabunde CN, Legler JM, Warren JL, et al. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17:584–590.
- Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258–1267.
- Cho H, Howlader N, Mariotto AB, et al. Technical report #2011-01: estimating relative survival for cancer patients from the SEER Program using expected rates based on Ederer I versus Ederer II method. National Cancer Institute Surveillance Research Program; 2011.
- Dickman PW, Sloggett A, Hills M, et al. Regression models for relative survival. Stat Med. 2004;23:51–64.
- Ederer F, Heise H. Methodological note no. 10: instructions to IBM 650 programmers in processing survival computations. Bethesda (MD): National Cancer Institute End Results Evaluation Section; 1959.
- van de Schans SA, van Steenbergen LN, Coebergh JW, et al. Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands. Haematologica. 2014;99:339–345.